Read More Pharma Industry News BridgeBio Pharma’s Acoramidis Phase 3 trial in ATTR-CM hits primary endpoint BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company specializing in genetic diseases and cancers, announced that the… byPallavi MadhirajuAugust 28, 2023